{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.61","upperLimit":"51.75","value":"44.02"},{"groupId":"OG001","lowerLimit":"29.14","upperLimit":"45.77","value":"37.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from date of randomization to the date of death due to any cause. Analyses were performed using all deaths in the FAS population regardless of whether they were observed during the double-blind treatment period, the open-label treatment period, the post-treatment evaluations, or the survival follow-up period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) included all randomized patients.","reportingStatus":"POSTED","timeFrame":"Baseline, to death- no time limit","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}